Erwin Robin

2.1k total citations
33 papers, 836 citations indexed

About

Erwin Robin is a scholar working on Oncology, Cardiology and Cardiovascular Medicine and Hematology. According to data from OpenAlex, Erwin Robin has authored 33 papers receiving a total of 836 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Cardiology and Cardiovascular Medicine and 9 papers in Hematology. Recurrent topics in Erwin Robin's work include Acute Myeloid Leukemia Research (7 papers), Hematopoietic Stem Cell Transplantation (5 papers) and Cancer Treatment and Pharmacology (5 papers). Erwin Robin is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Hematopoietic Stem Cell Transplantation (5 papers) and Cancer Treatment and Pharmacology (5 papers). Erwin Robin collaborates with scholars based in United States and Greece. Erwin Robin's co-authors include Azra Raza, Richard J. Bing, Nora Goldschlager, Sefer Gezer, Saleem Dar, Parameswaran Venugopal, Stephanie Gregory, Sairah Alvi, Agapi Parcharidou and Agustin Arbulu and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Erwin Robin

32 papers receiving 776 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erwin Robin United States 18 311 211 178 143 119 33 836
Irma O. Szymanski United States 16 335 1.1× 94 0.4× 105 0.6× 76 0.5× 88 0.7× 39 925
J. A. McBride United States 15 300 1.0× 60 0.3× 136 0.8× 166 1.2× 101 0.8× 33 876
Abraham Kornberg Israel 17 346 1.1× 164 0.8× 189 1.1× 80 0.6× 88 0.7× 54 925
G Duhamel France 14 420 1.4× 92 0.4× 127 0.7× 168 1.2× 70 0.6× 65 1.0k
Renate Thalhammer Austria 14 393 1.3× 196 0.9× 181 1.0× 405 2.8× 84 0.7× 35 1.0k
Monica Attanasio Italy 20 224 0.7× 391 1.9× 155 0.9× 104 0.7× 215 1.8× 44 1.1k
Herbert Wohl United States 12 376 1.2× 111 0.5× 100 0.6× 99 0.7× 323 2.7× 25 949
Thompson Cb United States 8 250 0.8× 178 0.8× 48 0.3× 269 1.9× 128 1.1× 9 633
L. A. Robbie United Kingdom 16 450 1.4× 112 0.5× 95 0.5× 40 0.3× 295 2.5× 29 955
A. Sagripanti Italy 17 226 0.7× 118 0.6× 79 0.4× 83 0.6× 139 1.2× 62 842

Countries citing papers authored by Erwin Robin

Since Specialization
Citations

This map shows the geographic impact of Erwin Robin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erwin Robin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erwin Robin more than expected).

Fields of papers citing papers by Erwin Robin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erwin Robin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erwin Robin. The network helps show where Erwin Robin may publish in the future.

Co-authorship network of co-authors of Erwin Robin

This figure shows the co-authorship network connecting the top 25 collaborators of Erwin Robin. A scholar is included among the top collaborators of Erwin Robin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erwin Robin. Erwin Robin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shaib, Walid L., Manali Rupji, Yuan Liu, et al.. (2023). Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). European Journal of Cancer. 189. 112847–112847. 7 indexed citations
2.
Galsky, Matt D., Sumanta K. Pal, Amir Mortazavi, et al.. (2019). Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.. Journal of Clinical Oncology. 37(15_suppl). 4504–4504. 17 indexed citations
3.
Fisher, William B., Rafat Ansari, Erwin Robin, et al.. (2012). Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Groupe. Journal of Thoracic Oncology. 7(4). 760–763. 22 indexed citations
4.
Schmitt, John, et al.. (2011). Sunitinib plus paclitaxel in patients with advanced esophageal cancer: A phase II study from the Hoosier Oncology Group.. Journal of Clinical Oncology. 29(15_suppl). e14661–e14661. 5 indexed citations
5.
Eklund, John, Mark Kozloff, Borko Jovanovic, et al.. (2006). Phase II study of mitoxantrone and ketoconazole for hormone‐refractory prostate cancer. Cancer. 106(11). 2459–2465. 20 indexed citations
6.
Burks, James, et al.. (2001). Familial Dilated Cardiomyopathy. Congestive Heart Failure. 7(3). 163–165. 2 indexed citations
7.
Raza, Azra, Laurie Lisak, Saleem Dar, et al.. (2000). Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood. 95(5). 1580–1587. 59 indexed citations
8.
Goyal, Rajat, Irfan Ali, Saleem Dar, et al.. (1999). Biologic characteristics of patients with hypocellular myelodysplastic syndromes. Leukemia Research. 23(4). 357–364. 18 indexed citations
9.
Raza, Azra, Sairah Alvi, Lambert F. R. Span, et al.. (1997). Excessive Proliferation Matched by Excessive Apoptosis in Myelodysplastic Syndromes: The Cause-Effect Relationship. Leukemia & lymphoma. 27(1-2). 111–118. 46 indexed citations
10.
Shetty, Vilasini, Suneel Mundle, Sairah Alvi, et al.. (1996). Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leukemia Research. 20(11-12). 891–900. 156 indexed citations
11.
12.
Williams, Stephanie, Jacob D. Bitran, Lynne Kaminer, et al.. (1987). A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer.. Journal of Clinical Oncology. 5(2). 260–265. 45 indexed citations
13.
Robin, Erwin, et al.. (1981). Induction of lymphomas in mice by busulfan and chloramphenicol.. PubMed. 41(9 Pt 1). 3478–82. 16 indexed citations
14.
Robin, Erwin, et al.. (1976). Correlation of Cold Pressor Response With Coronary Atherosclerosis and Left Ventricular Performance. Angiology. 27(1). 42–52. 4 indexed citations
15.
Robin, Erwin, et al.. (1975). Hemodynamic consequences of total removal of the tricuspid valve without prosthetic replacement. The American Journal of Cardiology. 35(4). 481–486. 45 indexed citations
16.
Robin, Erwin, et al.. (1974). Consequences of total tricuspid valvulectomy without prosthetic replacement in treatment of Pseudomonas endocarditis. Journal of Thoracic and Cardiovascular Surgery. 68(3). 461–465. 7 indexed citations
17.
Robin, Erwin, et al.. (1974). Detection of Tricuspid Valve Vegetations by Echocardiography. CHEST Journal. 66(4). 432–433. 25 indexed citations
18.
Leb, G., et al.. (1970). THE EFFECT OF NICOTINE ON EFFECTIVE AND TOTAL CORONARY BLOOD FLOW IN THE ANESTHETIZED CLOSED-CHEST DOG. Journal of Pharmacology and Experimental Therapeutics. 173(1). 138–144. 17 indexed citations
19.
Goldschlager, Nora, et al.. (1969). The Effect of Glucagon on the Coronary Circulation in Man. Circulation. 40(6). 829–837. 14 indexed citations
20.
Robin, Erwin, et al.. (1967). A Comparative Study of Nitroglycerin and Propranolol. Circulation. 36(2). 175–186. 84 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Irma O. Szymanski Breakdown of academic impact, for papers by J. A. McBride Breakdown of academic impact, for papers by Abraham Kornberg Breakdown of academic impact, for papers by G Duhamel Breakdown of academic impact, for papers by Renate Thalhammer Breakdown of academic impact, for papers by Monica Attanasio Breakdown of academic impact, for papers by Herbert Wohl Breakdown of academic impact, for papers by Thompson Cb Breakdown of academic impact, for papers by L. A. Robbie Breakdown of academic impact, for papers by A. Sagripanti
Rankless by CCL
2026